DK2970512T3 - Immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf - Google Patents
Immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf Download PDFInfo
- Publication number
- DK2970512T3 DK2970512T3 DK14779937.3T DK14779937T DK2970512T3 DK 2970512 T3 DK2970512 T3 DK 2970512T3 DK 14779937 T DK14779937 T DK 14779937T DK 2970512 T3 DK2970512 T3 DK 2970512T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- val
- thr
- pro
- leu
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Fremgangsmåde til fremstilling af et terapeutisk aktivt fusionsprotein, hvor fusionsproteinet omfatter en tumor-targeting del og mindst et immunmodulato-risk molekyle, der modvirker en cancercelles immunologiske tolerance, hvor den tumor-targeting del er et antistof, der binder til EGFR1 eller CTLA-4, og hvor fusionsproteinet fremstilles ved følgende trin: at fremstille en kodon-optimeret nukleotidsekvens, der koder for fusionsproteinet til ekspression i CHO-celler, hvor den kodon-optimerede nukleotidsekvens er modificeret til øgning af CG-sekvenser, og hvor den kodon-optimerede nukleotidsekvens er SEQ ID NO: 1 eller 5 for den tunge kæde af antistoffet, SEQ ID NO: 2 eller 6 for den lette kæde af antistoffet, SEQ ID NO: 3 eller 7 for det immunmodulatoriske molekyle, hvor den kodon-optimerede nukleotidsekvens SEQ ID NO: 1 eller 5 for den tunge kæde af antistoffet, der binder til henholdsvis EGFR1 eller CTLA-4, ikke har nukleotider til ekspression af et lysin ved den C-terminale ende af den tunge kæde af antistoffet; at klone den optimerede sekvens af fusionsproteinet i de CHO-celler, der er i stand til transient eller stabil ekspression; at dyrke CHO-cellerne i et medium under betingelser, der er egnede til dyrkning, og lade værtscellen eksprimere fusionsproteinet; og at indsamle secernerede fusionsproteiner og eventuelt til yderligere oprensning.
2. Fremgangsmåde ifølge krav 1, hvor det immunmodulatoriske molekyle er bundet til antistoffet gennem en aminosyresekvens eksprimeret ved SEQ ID NO: 4 af tilstrækkelig længde til at muliggøre bispecifik binding af fusionsproteinet og er bundet direkte eller gennem en linker til den tunge kæde af antistoffet, den lette kæde af antistoffet eller begge kæder.
3. Fremgangsmåde ifølge krav 1, hvor det immunmodulatoriske molekyle er bundet direkte eller gennem en linker eksprimeret ved SEQ ID NO: 4 til N- eller C-terminus af den tunge kæde af antistoffet, N- eller C-terminus af den lette kæde af antistoffet eller både N- og C-terminus af begge kæder.
4. Fremgangsmåde ifølge krav 1, hvor de kodon-optimerede nukleotidsekven-ser omfatter SEQ ID NOs: 1,2, 4 og 7.
5. Fremgangsmåde ifølge krav 1, hvor de kodon-optimerede nukleotidsekven-ser omfatter SEQ ID NOs: 1,2, 3 og 4.
6. Fremgangsmåde ifølge krav 1, hvor de kodon-optimerede nukleotidsekven-ser omfatter SEQ ID NOs: 5, 6, 7 og 4.
7. Præparat omfattende homogene terapeutisk aktive fusionsproteiner, hvor fusionsproteinerne omfatter en tumor-targeting del og mindst et immunmodu-latorisk molekyle, hvor den tumor-targeting del er et antistof, der binder til EGFR1 eller CTLA-4, og hvor fusionsproteinerne er fremstillet i henhold til krav 1, hvor fusionsproteinet har en kodon-optimeret nukleotidsekvens, der koder for fusionsproteinet til ekspression i CHO-celler, hvor den kodon-optimerede nukleotidsekvens er modificeret til øgning af CG-sekvenser, og hvor den kodon-optimerede nukleotidsekvens er SEQ ID NO: 1 eller 5 for den tunge kæde af antistoffet, SEQ ID NO: 2 eller 6 for den lette kæde af antistoffet, SEQ ID NO: 3 eller 7 for det immunmodulatoriske molekyle, hvor den kodon-optimerede nukleotidsekvens SEQ ID NO: 1 eller 5 for den tunge kæde af antistoffet, der binder til henholdsvis EGFR1 eller CTLA-4, ikke har nukleotider til ekspression af et lysin ved den C-terminale ende af den tunge kæde af antistoffet.
8. Nukleinsyresekvens, der koder for det kimære fusionsprotein ifølge krav 1, hvor den tunge kæde og lette kæde er SEQ ID NO: 1 og 2 eller SEQ ID NO: 5 og 6, hvor den immunmodulerende target-del er SEQ ID NO: 3 eller 7.
9. Vektor omfattende nukleinsyresekvenserne ifølge krav 8.
10. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 9 og en blandt SEQ ID NOs: 15, 17, 27 eller 29.
11. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 8 og en blandt SEQ ID NOs: 16, 18, 28 eller 30.
12. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 31 og en blandt SEQ ID NOs: 28 eller 30.
13. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 29 og en blandt SEQ ID NOs: 28 eller 30.
14. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 32 og en blandt SEQ ID NOs: 14, 33 eller 35.
15. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 13 og en blandt SEQ ID NOs: 33 eller 35.
16. Fremgangsmåde ifølge krav 1, hvor fusionsproteinet omfatter aminosyre-sekvenserne med SEQ ID NOs: 34 og en blandt SEQ ID NOs: 14, 33 eller 35.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777016P | 2013-03-12 | 2013-03-12 | |
| PCT/US2014/022404 WO2014164427A1 (en) | 2013-03-12 | 2014-03-10 | Fusion immunomodulatory proteins and methods for making same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970512T3 true DK2970512T3 (da) | 2019-01-14 |
Family
ID=51658871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14779937.3T DK2970512T3 (da) | 2013-03-12 | 2014-03-10 | Immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9988456B2 (da) |
| EP (1) | EP2970512B1 (da) |
| JP (2) | JP6605444B2 (da) |
| CN (1) | CN105121474B9 (da) |
| AU (2) | AU2014249405C1 (da) |
| BR (1) | BR112015022733B1 (da) |
| CA (2) | CA2902830C (da) |
| DK (1) | DK2970512T3 (da) |
| ES (1) | ES2704411T3 (da) |
| MY (1) | MY186864A (da) |
| NZ (1) | NZ711445A (da) |
| PL (1) | PL2970512T3 (da) |
| PT (1) | PT2970512T (da) |
| RU (2) | RU2698975C2 (da) |
| WO (1) | WO2014164427A1 (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| WO2016135041A1 (en) * | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CN108348578B (zh) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| JP6981973B2 (ja) | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| WO2017134592A1 (en) * | 2016-02-03 | 2017-08-10 | Biocon Limited | Anti-cd20/immunomodulatory fusion proteins and methods for making same |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| BR112019005964A2 (pt) | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| US11739163B2 (en) | 2016-09-29 | 2023-08-29 | Aebi Ltd. | Therapeutic multi-targeting constructs and uses thereof |
| EP4249503A3 (en) | 2017-02-27 | 2023-12-20 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
| US20190367579A1 (en) | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| AU2018228435C1 (en) | 2017-03-02 | 2025-09-18 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
| ES2948647T3 (es) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas |
| MY202480A (en) * | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| EP3646887A4 (en) * | 2017-06-30 | 2021-03-24 | Korea Advanced Institute of Science and Technology | CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF |
| WO2019046859A1 (en) * | 2017-09-02 | 2019-03-07 | Abbvie Inc. | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
| WO2019046858A1 (en) * | 2017-09-02 | 2019-03-07 | Abbvie Inc. | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
| JP2020536518A (ja) | 2017-09-27 | 2020-12-17 | エピセントアールエックス，インコーポレイテッド | 免疫調節融合タンパク質 |
| WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| MX2020011846A (es) | 2018-05-06 | 2021-03-25 | Amai Proteins Ltd | Proteinas modificadoras del sabor y gusto. |
| WO2019222252A1 (en) * | 2018-05-15 | 2019-11-21 | Merck Patent Gmbh | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| US12559539B2 (en) | 2018-11-09 | 2026-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta receptor fusion protein pharmaceutical composition and use thereof |
| CN110563851B (zh) * | 2019-08-20 | 2020-06-12 | 启辰生生物科技(珠海)有限公司 | 具有免疫调节功能的融合蛋白、药物组合物、细胞及应用 |
| CN110734498A (zh) * | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| CN110964118A (zh) * | 2019-11-27 | 2020-04-07 | 中国药科大学 | 一种双特异性融合抗体及其在肿瘤免疫治疗中的应用 |
| EP4144764A4 (en) * | 2020-04-28 | 2024-07-17 | Sinocelltech Ltd. | TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2, FUSION PROTEIN OF TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2 AND ANTI-EGFR ANTIBODY, AND ANTITUMORAL USE OF FUSION PROTEIN |
| CN111690070A (zh) * | 2020-05-13 | 2020-09-22 | 深圳市众循精准医学研究院 | 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用 |
| WO2022057061A1 (en) * | 2020-09-16 | 2022-03-24 | Suzhou Neologics Bioscience Co., Ltd. | Pd-l1 antibodies, fusion proteins, and uses thereof |
| WO2022125396A1 (en) | 2020-12-10 | 2022-06-16 | Verily Life Sciences Llc | Wearable biosensor devices with adaptive power consumption |
| AU2021400979A1 (en) * | 2020-12-15 | 2023-06-29 | Bicara Therapeutics Inc. | Combination therapy for the treatment of cancer |
| AU2021400284A1 (en) * | 2020-12-15 | 2023-06-22 | Bicara Therapeutics Inc. | Pharmaceutical formulations for fusion proteins |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20240051277A (ko) * | 2021-09-03 | 2024-04-19 | 노바록 바이오테라퓨틱스 리미티드 | PD-L1, CD137, 및/또는 TGFβ에 대한 이중특이체 및 삼중특이체 결합 단백질 및 이의 용도 |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91778A (en) | 1988-09-28 | 1994-10-07 | Lilly Co Eli | A method for reducing the heterogeneity of monoclonal antibodies |
| RU2120475C1 (ru) * | 1990-05-17 | 1998-10-20 | Макс-Планк-Гезельшафт Цур Фердерунг дер Виссеншафтен е.ф. | Способ получения представляющего интерес полипептида, гибридная днк (варианты), слитый белок (варианты) |
| CA2279547A1 (en) | 1997-01-31 | 1998-08-06 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| WO2001055301A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| DE60236735D1 (de) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | Antikörper gegen vla-1 |
| ES2535877T3 (es) * | 2006-06-19 | 2015-05-18 | Asklepios Biopharmaceutical, Inc. | Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica |
| CA2671875A1 (en) | 2006-12-22 | 2008-06-03 | Ares Trading S.A. | Analytical method for analyzing c-terminus truncation |
| EP2031064A1 (de) * | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JP5304275B2 (ja) | 2009-01-29 | 2013-10-02 | Ｊｎｃ株式会社 | アポクライティン−ｉｉをコードするコドン最適化核酸およびその使用方法 |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| CN105189735B (zh) | 2011-04-29 | 2019-04-12 | 拜康研究有限公司 | 在培养期间减少乳酸累积的方法和生产多肽的方法 |
| KR101591671B1 (ko) | 2011-04-29 | 2016-02-04 | 바이오콘 리서치 리미티드 | 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법 |
| JP6454547B2 (ja) * | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
| US8604447B2 (en) | 2011-07-27 | 2013-12-10 | Kla-Tencor Corporation | Solar metrology methods and apparatus |
| SE536913C2 (sv) | 2012-03-08 | 2014-10-28 | Gambro Lundia Ab | Komposition för dialys |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| JP2018167875A (ja) * | 2017-03-30 | 2018-11-01 | 株式会社フジシール | 容器包装体及び容器包装体の製造方法 |
-
2014
- 2014-03-10 CA CA2902830A patent/CA2902830C/en active Active
- 2014-03-10 CA CA3081073A patent/CA3081073C/en active Active
- 2014-03-10 BR BR112015022733-3A patent/BR112015022733B1/pt active IP Right Grant
- 2014-03-10 ES ES14779937T patent/ES2704411T3/es active Active
- 2014-03-10 DK DK14779937.3T patent/DK2970512T3/da active
- 2014-03-10 WO PCT/US2014/022404 patent/WO2014164427A1/en not_active Ceased
- 2014-03-10 MY MYPI2015703125A patent/MY186864A/en unknown
- 2014-03-10 EP EP14779937.3A patent/EP2970512B1/en active Active
- 2014-03-10 PL PL14779937T patent/PL2970512T3/pl unknown
- 2014-03-10 AU AU2014249405A patent/AU2014249405C1/en active Active
- 2014-03-10 RU RU2018117558A patent/RU2698975C2/ru active
- 2014-03-10 JP JP2016500960A patent/JP6605444B2/ja active Active
- 2014-03-10 PT PT14779937T patent/PT2970512T/pt unknown
- 2014-03-10 US US14/771,308 patent/US9988456B2/en active Active
- 2014-03-10 CN CN201480015160.1A patent/CN105121474B9/zh active Active
- 2014-03-10 NZ NZ711445A patent/NZ711445A/en unknown
- 2014-03-10 RU RU2015140608A patent/RU2662991C2/ru active
-
2018
- 2018-04-30 AU AU2018202982A patent/AU2018202982B2/en active Active
- 2018-05-01 US US15/968,122 patent/US10766963B2/en active Active
- 2018-09-07 JP JP2018167875A patent/JP2019010111A/ja active Pending
-
2020
- 2020-09-02 US US17/010,178 patent/US12351636B2/en active Active
-
2025
- 2025-06-12 US US19/236,781 patent/US20250368743A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250368743A1 (en) | Fusion immunomodulatory proteins and methods for making same | |
| AU2017201572B2 (en) | Targeted/immunomodulatory fusion proteins and methods for making same | |
| WO2017134592A1 (en) | Anti-cd20/immunomodulatory fusion proteins and methods for making same | |
| WO2025190373A1 (en) | Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and use thereof | |
| HK1217343B (zh) | 融合免疫调节蛋白及其制备方法 | |
| HK40016816A (en) | Targeted/immunomodulatory fusion proteins and methods for making same | |
| HK40008894A (en) | Targeted/immunomodulatory fusion proteins and methods for making same |